Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)
Taiwan · Delayed Price · Currency is TWD 31.25
+0.30 (0.97%)
Mar 24, 2026, 1:30 PM CST
Sinphar Pharmaceutical Revenue
In the year 2025, Sinphar Pharmaceutical had annual revenue of 3.37B TWD with 7.00% growth. Sinphar Pharmaceutical had revenue of 880.02M in the quarter ending December 31, 2025, with 3.00% growth.
Revenue
3.37B
Revenue Growth
+7.00%
P/S Ratio
1.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.37B | 220.69M | 7.00% |
| Dec 31, 2024 | 3.15B | 187.69M | 6.33% |
| Dec 31, 2023 | 2.96B | 106.28M | 3.72% |
| Dec 31, 2022 | 2.86B | 423.14M | 17.39% |
| Dec 31, 2021 | 2.43B | 45.06M | 1.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Panion & Bf Biotech | 2.06B |
| Savior Lifetec | 1.20B |
| Mycenax Biotech | 740.24M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| UnicoCell Biomed | 30.10M |
| AnnJi Pharmaceutical | 23.85M |
| CHO Pharma | 3.21M |